Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(60%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Active, not recruiting2
Not yet recruiting1
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

not_yet_recruiting120%
active_not_recruiting240%
recruiting120%
completed120%

Recent Activity

3 active trials
Showing 5 of 5
not_yet_recruitingphase_2

Testing the SurVaxM Vaccine for Lung Cancer Prevention

NCT07169617
active_not_recruitingphase_2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

NCT02455557
recruitingphase_2

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

NCT06202066
completedphase_1

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

NCT03879694
active_not_recruitingphase_1

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

NCT02334865

Clinical Trials (5)

Showing 5 of 5 trials
NCT07169617Phase 2

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not Yet Recruiting
NCT02455557Phase 2

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active Not Recruiting
NCT06202066Phase 2

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Recruiting
NCT03879694Phase 1

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Completed
NCT02334865Phase 1

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Active Not Recruiting

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5